Established: 2013

Country: AUS

City: Melbourne

Employees: NA

Homepage

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Invesco International Corporate Bond ETF

Industrial Select Sector SPDR Fund

Invesco High Yield Bond Factor ETF

Marine Bancorp FLA Inc

Kingdee International Software Group Co Ltd